Cover of Clinical Review Report: Doravirine (Pifeltro)

Clinical Review Report: Doravirine (Pifeltro)

(Merck Canada Inc.)

Indication: Doravirine (Pifeltro) is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine

CADTH Common Drug Review

Copyright © 2019 Canadian Agency for Drugs and Technologies in Health.
Read

The objective of this systematic review was to evaluate the beneficial and harmful effects of doravirine, in combination with other antiretroviral medicinal products, for the treatment of HIV-1 infection in adults without past or present evidence of viral resistance to Doravirine.